All Outputs (5)

Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience (2023)
Journal Article
Shotton, R., Broadbent, R., Alchawaf, A., Mohamed, M. B., Gibb, A., Martinez-Calle, N., …Linton, K. M. (2023). Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience. Blood Advances, 8(4), 878-888. https://doi.org/10.1182/bloodadvances.2023011305

Bendamustine is among the most effective chemotherapeutics for indolent B-cell non- Hodgkin lymphomas (iNHL), but trial reports of significant toxicity, including opportunistic infections and excess deaths, led to prescriber warnings. We conducted a... Read More about Safety of bendamustine for the treatment of indolent non-Hodgkin lymphoma: a UK real-world experience.

Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline (2023)
Journal Article
Eyre, T. A., Bishton, M. J., McCulloch, R., O'Reilly, M., Menon, G., Iyengar, S., …Haemato-Oncology Task Force of the British Society for Haematology, H. T. F. O. T. B. S. F. H. (2024). Diagnosis and Management of Mantle Cell Lymphoma: A British Society for Haematology Guideline. British Journal of Haematology, 204(1), 108-126. https://doi.org/10.1111/bjh.19131

High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma (2023)
Journal Article
Lewis, K. L., Jakobsen, L. H., Villa, D., Smedby, K. E., Savage, K. J., Eyre, T. A., …Pophali, P. A. (2023). High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma. Journal of Clinical Oncology, 41(35), 5376-5387. https://doi.org/10.1200/JCO.23.00365

PURPOSE
CNS progression or relapse is an uncommon but devastating complication of aggressive B-cell lymphoma. There is no consensus regarding the optimal approach to CNS prophylaxis. This study was designed to determine whether high-dose methotrexat... Read More about High-Dose Methotrexate as CNS Prophylaxis in High-Risk Aggressive B-Cell Lymphoma.

Incidence and Survival in Patients With Enteropathy-associated T-Cell Lymphoma: Nationwide Registry Studies From England and Denmark (2023)
Journal Article
West, J., Jepsen, P., Card, T. R., Crooks, C. J., & Bishton, M. (2023). Incidence and Survival in Patients With Enteropathy-associated T-Cell Lymphoma: Nationwide Registry Studies From England and Denmark. Gastroenterology, 165(4), 1064-1066.e3. https://doi.org/10.1053/j.gastro.2023.06.003

1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018 (2023)
Journal Article
West, J., Stilwell, P., Liu, H., Ban, L., Bythell, M., Card, T., …Crooks, C. (2023). 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018. Journal of Hematology and Oncology, 16, Article 56. https://doi.org/10.1186/s13045-023-01434-4

Haemophagocytic lymphohistiocytosis (HLH) is a lethal syndrome of excessive immune activation. We undertook a nationwide study in England of all cases of HLH diagnosed between 2003 and 2018, using linked electronic health data from hospital admission... Read More about 1-year survival in haemophagocytic lymphohistiocytosis: a nationwide cohort study from England 2003–2018.